Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25342607 | 0.89 | NR1H2 (0.35) | GPR119PDK2GPR183HRH3ESR2 | |
| SCHEMBL31024694 | 0.78 | GPR119 (0.42) | GPR119PDK2HRH3NR1H2 | |
| SCHEMBL25342433 | 0.75 | GRIN2D (0.32) | — | |
| SCHEMBL19030641 | 0.72 | ESR2 (0.39) | GPR119GPR183HRH3ESR2NR1H2 | |
| SCHEMBL25343723 | 0.72 | GPR119 (0.49) | GPR119HRH3SMN1; SMN2USP2 | |
| SCHEMBL30746323 | 0.72 | GPR119 (0.38) | GPR119GPR183HRH3SCD5USP2 | |
| SCHEMBL27095258 | 0.72 | GPR119 (0.38) | GPR119GPR183HRH3SCD5USP2 | |
| SCHEMBL23051565 | 0.69 | SCD5 (0.40) | GPR119GPR183USP30ESR2SMN1; SMN2 | |
| SCHEMBL25344433 | 0.68 | GPR119 (0.40) | GPR119USP30HRH3SMN1; SMN2SCD5 | |
| SCHEMBL30094665 | 0.67 | HSD11B1 (0.51) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2025026283-A1 | COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF | 甘李药业股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4471033-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024156294-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | 甘李药业股份有限公司 | 2024-08-02 | — | — | WO | disclosed |
| WO-2023143589-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | GPR119 2388/4885PDK2 3811/4885GPR183 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.